Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610772 | 0.78 | KDM4E (0.35) | POLBMAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL7606156 | 0.74 | MAPT (0.33) | MAPTKDM4EALDH1A1MAPK1MEN1 | |
| SCHEMBL7610123 | 0.74 | KDM4E (0.36) | MAPTKDM4EALDH1A1MAPK1MEN1 | |
| SCHEMBL6738535 | 0.71 | MAPT (0.47) | POLBMAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL6930289 | 0.68 | KDM4E (0.33) | MAPTKDM4EALDH1A1MAPK1MEN1 | |
| SCHEMBL20756510 | 0.64 | ALDH1A1 (0.45) | POLBMAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL15723646 | 0.64 | KDM4E (0.32) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6732775 | 0.63 | GAA (0.43) | GAA | |
| SCHEMBL15724374 | 0.60 | LMNA (0.40) | POLBKDM4EALDH1A1MAPK1MEN1 | |
| SCHEMBL24007329 | 0.59 | HCRTR1 (0.38) | POLBKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020031536-A1 | Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof | L'OREAL SA | 2002-03-14 | — | — | US | disclosed |
| US-6322775-B1 | FOR COLORING THE SKIN AND/OR THE HAIR; SIDE EFFECTS REDUCTION; STABILITY | L'OREAL S.A. (FR) | 2001-11-27 | — | — | US | disclosed |
| EP-0888306-B1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | OREAL (FR) | 2001-07-25 | — | — | EP | disclosed |
| EP-0888306-A1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | L'OREAL (FR) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997035842-A1 | COSMETIC COMPOSITIONS CONTAINING PYRAZOLIN-4,5-DIONES, NOVEL PYRAZOLIN-4,5-DIONES, PREPARATION METHODS THEREFOR AND USES THEREOF | L'OREAL (FR) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020031536-A1 | Cosmetic compositions based on 4,5-pyrazolinediones, novel 4,5-pyrazolinediones, process for their preparation and uses thereof | PPARD, PLIN5, PDK4 | POLB 1971/4885MAPT 3025/4885KDM4E 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.